Theorem Clinical Research

R&D Trends

Survey shows support for increased stem cell research

Thursday, July 10, 2014 12:48 PM

Americans are in broad support of more stem cell research, according to the results of an online survey released by Cord Blood Registry (CBR) to coincide with National Cord Blood Awareness Month.

More... »


VC investment in healthcare sector soars in second quarter

Thursday, July 10, 2014 06:03 AM

By Ronald Rosenberg
CenterWatch Staff Writer

More than 50% of all initial public offerings in the second quarter of 2014 were healthcare companies, as 24 venture capital-backed firms became publicly traded, compared to a more robust first quarter of 35 IPOs. 

More... »


Sorrento awarded up to $2.6M from NIH for bispecific antibodies

Wednesday, July 9, 2014 12:12 PM

Sorrento Therapeutics, a late-stage clinical oncology company developing new treatments for cancer and its associated pain, has received two NIH small business grants, which will fund the development of bispecific antibodies for two of its anti-bacterial immunotherapies. Sorrento's highly diverse, fully human G-MAB library and proprietary antibody conjugation technology platforms have broad applications beyond oncology, including other therapeutic areas such as anti-infectives and auto-immune diseases.

More... »

Report: cancer immunotherapy market to hit $9B globally by 2022

Wednesday, July 9, 2014 12:05 PM

Decision Resources Group reports the immunotherapy market will experience considerable growth through 2022, increasing from $1.1 billion in 2012 to nearly $9 billion in 2022 (corresponding to 23.8% annual growth) in the U.S., France, Germany, Italy, Spain, U.K. and Japan.

More... »

AstraZeneca, Max Planck Institute to create satellite chemistry unit

Wednesday, July 9, 2014 12:03 PM

The Max Planck Institute of Molecular Physiology (MPI), Germany, will establish a satellite unit in cardiovascular and metabolic disease (CVMD) with AstraZeneca's CVMD Innovative Medicines unit (iMed) in Mölndal, Sweden, to study new modalities chemistry.

More... »

Portola, Daiichi Sankyo to collaborate on andexanet alfa study

Wednesday, July 9, 2014 12:01 PM

Portola Pharmaceuticals has entered into a second clinical collaboration agreement with Daiichi Sankyo to study andexanet alfa, Portola's investigational Factor Xa inhibitor antidote, in phase III registration studies with Daiichi Sankyo's Factor Xa inhibitor edoxaban. Portola's original collaboration agreement with Daiichi Sankyo, announced in June 2013, covered the conduct of a phase II proof-of-concept study, for which results are anticipated later this year.

More... »

Alzheimer’s Research U.K. calls for increased investment in Alzheimer’s drug trials

Monday, July 7, 2014 10:08 AM

Alzheimer’s Research U.K. calls for increased investment in Alzheimer’s drug trials after a comprehensive study of all of the clinical trials for Alzheimer’s drugs in the U.S. highlighted a very high failure rate of the drugs being tested. The study, published in Alzheimer’s Research and Therapy, found that 99.6% of trials of potential Alzheimer’s treatments aimed at preventing, curing or improving the symptoms of the disease failed or were discontinued.

More... »

CureVac, Sanofi Pasteur ink agreement to develop mRNA-based prophylactic vaccine

Thursday, July 3, 2014 10:00 AM

CureVac, a German-based clinical-stage biopharmaceutical company, has inked an agreement with Sanofi Pasteur, the vaccines division of Sanofi, to develop and commercialize an mRNA-based vaccine against an undisclosed pathogen.

More... »

NIH adds six clinical sites in Undiagnosed Diseases Network

Wednesday, July 2, 2014 12:40 PM

The NIH has awarded grants to six medical centers around the country to select from the most difficult-to-solve medical cases and together develop effective approaches to diagnose them. The new clinical sites added to the NIH Undiagnosed Diseases Network (UDN) will conduct clinical evaluation and scientific investigation in cases that involve patients with prolonged, undiagnosed conditions.

More... »

Trovagene inks agreement with Lurie Comprehensive Cancer Center, NMDTI

Monday, June 30, 2014 03:35 PM

Trovagene has partnered with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) to conduct a translational research program designed to assess the utility of Trovagene's urine-based cell-free oncogene mutation monitoring technology in clinical practice.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 15

WIRB-Copernicus Group acquires New England IRB

BBK Worldwide secures $3 million in private ἀnancingto accelerate its global and technological expansion

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs